anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The intervention programme will be implemented for 6 months. Nutrition education is developed through piloting a health promoting school model, the content will combine the government programme "healthy school" and WHO cartoon pamphlets distributed to each school/student in the intervention school. Nutrition and health education was provided 6 times for students, and 2 times for parents and 4 times for teachers and UKS officers. Physical activity intervention School-based physical activity programme for students called "Happy in school children" Other forms of physical activity included games, dance or rhythmic gymnastics, such as jumping rope, and squatting, or by adjusting the curriculum. And piloting the health promoting school (HPS) model, the expected outcome of the health promoting school (HPS) model is health literacy.
Ankylosing spondylitis is a chronic inflammatory disease, which mainly invades sacroiliac joint, spinal osteoid process, paraspinal soft tissue and peripheral joints, and can be accompanied by extraarticular manifestations, in severe cases, spinal deformity and ankylosis can occur. The overall prevalence rate of ankylosing spondylitis in China is about 0.3%, the peak of which is 20 to 30 years old. although the prevalence rate is not high, the disability rate is high, and the patients with ankylosing spondylitis are mainly young people of childbearing age, which are in a critical period of work and study. If the disease can not be controlled smoothly, it will seriously affect its learning and work efficiency, image appearance and even the ability of daily life.

Bawei Shenqi Pill originates from Zhang Zhongjing's synopsis of the Golden Chamber, is the representative prescription of warming and tonifying kidney yang, and is also suitable for the pathogenesis of ankylosing spondylitis "deficiency of kidney yang". The purpose of this study was to observe the therapeutic effect of Bawei Shenqi Pill on ankylosing spondylitis of kidney-yang deficiency type through a randomized controlled clinical study. To clarify the effect of Bawei Shenqi Pill on disease activity, joint function, TCM syndrome integral and quality of life in patients with ankylosing spondylitis, and to provide basis for the treatment of ankylosing spondylitis with Bawei Shenqi Pill.
A crystal comprising an androgen receptor ligand binding domain (AR-LBD) is provided. The crystal structures of the human Androgen Receptor Ligand Binding Domain (hAR-LBD) in comparison with the human Progesterone Receptor Ligand Binding Domains (hPR-(hPR-LBD) complexed with the same ligand metribolone (R1881) are also provided. The three-dimensional structures of the hAR LBD as well as the hPR LBD show the typical nuclear receptor fold. The change of two residues in the ligand binding pocket (LBP) between hPR and hAR seems to be the most likely source for the specificity of the R1881 ligand binding to hAR LBD. The structural implications of the 14 known mutations in the LBP of the hAR LBD associated with either prostate cancer (PC) or the partial androgen receptor insensitivity syndrome (PAIS) or complete androgen receptor insensitivity syndrome (CAIS) are analysed. The effects of most of these mutants may be explained on the basis of the crystal structure.
The invention relates to the field of microbes and novel drugs and pesticides, and concretely relates to a marine Actinoalloteichus sp. and an application thereof. The Actinoalloteichus sp. is Actinoalloteichus sp.SHA6, and is preserved in China Center for Type Culture Collection on Feb. 20, 2014 with the preservation number of CCTCC M2014041. Maclafungin compounds generated by the Actinoalloteichus sp. are represented by formula (I). The maclafungin compounds represented by formula (I) have substantial antifungal and insecticidal effects, and can be used as ideal antibiotic and insecticidal candidate compounds. The compounds can be produced through microbial fermentation, a preparation method of the compounds is simple and efficient, and the compounds are highly pure. The Actinoalloteichus sp. and the compounds have good application prospects. In the formula I, R1 is H or CH3; and R2 is H or CH3.
The invention provides application of HDAC5 genes in regulating and controlling P-glycoprotein expression under a hypoxia state. The regulation is negative regulation, and when the expression of the HDAC5 gene is down-regulated, the expression of the P-glycoprotein is up-regulated; when HDAC5 gene expression is up-regulated, P-glycoprotein expression is down-regulated. The invention proves that HDAC5 is up-regulated and P-gp is down-regulated in a liver cell hypoxia model of a hypoxia rat; there is a negative regulatory relationship between HDAC5 and P-gp. Under plateau hypoxia conditions, HDAC5 is up-regulated and P-gp is down-regulated; the removal rate of phenytoin sodium decreases. The pharmacokinetic profile and parameters were also altered with the administration of agonist and inhibitor, respectively. According to the invention, through research on pharmacokinetics of the P-gp substrate, HDAC5 has obvious capability of regulating and controlling P-gp, and can influence the pharmacokinetics of the P-gp substrate, so that the invention has important significance on reasonable administration of the medicine on the plateau.
For adult and adolescent patients weighing greater than or equal to 50 kg requiring 1,000 mg doses of Acetaminophen Injection, administer by intravenous infusion. Acetaminophen Injection may be administered without further dilution. Examine the bag contents before dose preparation or administering. DO NOT USE if particulate matter or discoloration is observed. Check for minute leaks by firmly squeezing the bag. If leaks are detected, discard the solution, as sterility may be impaired. Keep the infusion bags in the overwrap until ready to use. Administer the contents of the bag intravenously over 15 minutes. Use aseptic technique when preparing Acetaminophen Injection for intravenous infusion. Do not add other medications to the Acetaminophen Injection bag or infusion device.

For doses less than 1,000 mg, the appropriate dose must be withdrawn from the bag and placed into a separate container prior to administration. Using aseptic technique, withdraw the appropriate dose (650 mg or weight-based) from an intact Acetaminophen Injection bag and place the measured dose in a separate empty, sterile container (e.g., glass bottle, plastic intravenous container, or syringe) for intravenous infusion to avoid the inadvertent delivery and administration of the total volume of the commercially available container. The entire 100 mL bag of Acetaminophen Injection is not intended for use in patients weighing less than 50 kg. Acetaminophen Injection is a single-dose bag and the unused portion must be discarded.

Place small volume pediatric doses up to 60 mL in volume in a syringe and administer over 15 minutes using a syringe pump.  


Monitor the end of the infusion in order to prevent the possibility of an air embolism, especially in cases where the Acetaminophen Injection infusion is the primary infusion.  


After opening the overwrap, immediate use of Acetaminophen Injection is recommended. However the stability of the product after it has been removed from the overwrap has been demonstrated for 24 hours.  


Do not add other medications to the Acetaminophen Injection solution. Diazepam and chlorpromazine hydrochloride are physically incompatible with Acetaminophen Injection, therefore do not administer simultaneously.
Total knee arthroplasty (TKA) is associated with intense early postoperative pain. Effective pain management following total knee arthroplasty is imperative to facilitate early ambulation, mobilization and rehabilitation. The postoperative pain regimen should enhance functional recovery in addition to providing efficient analgesia with minimal side effects. To manage postoperative pain effectively, multimodal analgesia including acetaminophen, Toradol, Solu-Medrol, opioids and local anesthetics are used. Periarticular infiltration performed intra-operatively combined with ultrasound guided adductor-canal peripheral nerve blocks are effective in reducing pain following a TKA without causing quadriceps motor block which can impede mobilization. There are no published trials that the investigators could find to date, comparing adductor canal block with a single dose Exparel and adductor canal block with standard ropivacaine.

A liposome is a manufactured spherical lipid vesicle that can be used to slowly release a drug thereby extending its duration of action. Exparel is such a compound that slowly releases bupivacaine. Local anesthetics block the conduction of all excitable tissue in a dose related fashion. The first tissues that are affected are nerves, which make these drugs of choice in neural block. Their local adverse effects include neurovascular manifestations are prolonged numbness, tingling, feeling of "pins and needles" or strange sensations. These effects are reversed with time. There are no additional potential risks or adverse effects due to the procedures or drugs being administered. The procedure is well established and the local anesthetics have a history of long term use in humans.
Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.
Ampicillin is similar to benzyl penicillin in its bactericidal action against susceptible organisms during the stage of active multiplication. It acts through the inhibition of cell wall mucopeptide biosynthesis. Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. (Ampicillin is, however, degraded by beta-lactamases and therefore the spectrum of activity does not normally include organisms which produce these enzymes).

A wide range of beta-lactamases found in microorganisms resistant to penicillins and cephalosporins have been shown in biochemical studies with cell free bacterial systems to be irreversibly inhibited by sulbactam. Although sulbactam alone possesses little useful antibacterial activity except against the Neisseriaceae, whole organism studies have shown that sulbactam restores ampicillin activity against beta-lactamase producing strains. In particular, sulbactam has good inhibitory activity against the clinically important plasmid mediated beta-lactamases most frequently responsible for transferred drug resistance. Sulbactam has no effect on the activity of ampicillin against ampicillin susceptible strains.

The presence of sulbactam in the ampicillin and sulbactam for injection formulation effectively extends the antibacterial spectrum of ampicillin to include many bacteria normally resistant to it and to other beta-lactam antibacterials. Thus, ampicillin and sulbactam for injection possesses the properties of a broad-spectrum antibacterial and a beta-lactamase inhibitor.

While in vitro studies have demonstrated the susceptibility of most strains of the following organisms, clinical efficacy for infections other than those included in the INDICATIONS and USAGE section has not been documented.

Gram-Positive Bacteria:Staphylococcus aureus (beta-lactamase and non-beta-lactamase producing), Staphylococcus epidermidis (beta-lactamase and non-beta-lactamase producing), Staphylococcus saprophyticus (beta-lactamase and non-beta-lactamase producing), Streptococcus faecalis† (Enterococcus), Streptococcus pneumoniae† (formerly D. pneumoniae), Streptococcus pyogenes†, Streptococcus viridans†.

Gram-Negative Bacteria:Hemophilus influenzae (beta-lactamase and non-beta-lactamase producing), Moraxella (Branhamella) catarrhalis (beta-lactamase and non-beta-lactamase producing), Escherichia coli (beta-lactamase and non-beta-lactamase producing), Klebsiella species (all known strains are beta-lactamase producing), Proteus mirabilis (beta-lactamase and non-beta-lactamase producing), Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Morganella morganii, and Neisseria gonorrhoeae (beta-lactamase and non-beta-lactamase producing).

Anaerobes:Clostridium species,† Peptococcus species,† Peptostreptococcus species, Bacteroides species, including B. fragilis.

† These are not beta-lactamase producing strains and, therefore, are susceptible to ampicillin alone.
Metastasis in breast cancer is the major cause of death in females (about 30%). Based on our earlier observation that Vitamin D3 downregulates mTOR, we hypothesized that Vitamin D3 conjugated to gold nanoparticles (VD3-GNPs) reduces breast cancer aggressiveness by downregulating the key cancer controller PI3K/AKT/mTOR. Western blots, migration/invasion assays, and other cell-based, biophysical, and bioinformatics studies are used to study breast cancer cell aggressiveness and nanoparticle characterization. Our VD3-GNP treatment of breast cancer cells (MCF-7 and MDA-MB-231) significantly reduces the aggressiveness (cancer cell migration and invasion rates > 45%) via the simultaneous downregulation of ETV7 and the Hippo pathway. Consistent with our hypothesis, we, indeed, found a downregulation of the PI3K/AKT/mTOR pathway. It is surprising that the extremely low dose of VD3 in the nano formulation (three orders of magnitude lower than in earlier studies) is quite effective in the alteration of cancer invasiveness and cell signaling pathways. Clearly, VD3-GNPs are a viable candidate for non-toxic, low-cost treatment for reducing breast cancer aggressiveness.
The present invention relates to a method for preparing compound micron dendrobium candicum soymilk powder for nourishing yin, reducing blood sugar and allaying fatigue. Micron dendrobium candicum powder, micron ophiopogon root powder, micron sea buckthorn powder, micron wolfberry fruit powder, micron amino acid chromium powder, sorbitol powder, etc. through high-technology airflow superfine grinding processing are added into different soymilk powder and processed into the soymilk powder for nourishing yin, reducing blood sugar and allaying fatigue in a combining mode. The present invention has the obvious function of reducing blood sugar and simultaneously has the effects on nourishing yin, benefiting lungs, allaying fatigue, enhancing immunity, etc. Diabetics can obtain scores of nutrient substances such as abundant protein, vitamins, mineral substances, active ferment, etc., and simultaneously, the present invention strengthens the health-care functions of nourishing yin, benefiting lungs, reducing blood sugar and supplementing calcium because the raw material such as the amino acid chromium powder, etc. which is extolled as a blood sugar reducing factor is added. Therefore, the present invention is a favorable method for preparing the soymilk powder for nourishing yin, reducing blood sugar and allaying fatigue, the soymilk powder has Chinese characteristics, and the soymilk powder is used for health care and longevity and especially designed for middle-aged diabetics and old diabetics all over the world.
Part A will be comprised of up to 50 participants over 5 cohorts of 10. Each participant will receive a single oral dose of TLC-2716 or placebo at different dose levels (1 cohort per dose level).
BACKGROUND: Tuberculous meningitis (TBM) accounts for about 1% of all tuberculosis cases and about 5% of extrapulmonary tuberculosis cases. However, it poses major importance because approximately half of those affected die or become severely disabled. Herein, the successful treatment of an 11-month-old boy with progressive limb weakness, fever, developmental retardation, and loss of consciousness due to tuberculosis, was reported.
CASE PRESENTATION: An 11-month-old (Iranian Turk) boy was referred to Loghman Hakim hospital for progressive limb weakness and loss of previously attained developmental milestones for the past 2 months. He also had persistent fever and loss of consciousness for about 14 to 21 days. Before being referred to our center, the patient had been diagnosed with hydrocephalus at another center due to possible acute bacterial meningitis based on a CT scan and MRI imaging. On physical examination, anterior fontanel bulging and neck stiffness were observed on the admission. His body temperature and heart rate were 38.1 C and 86 beats per minute (bpm), respectively. He had left 6 cranial nerve palsy and spastic quadriparesis with a power of grade 3/5. Other systemic examinations were normal. Endoscopic third ventriculostomy (ETV) (and leptomeningeal biopsy) revealed diffuse thickening of the floor and lateral walls of the 3rd ventricle and also a cobblestone appearance in the form of multiple white patchy lesions was detected on the floor of the 3rd ventricle. CSF analysis and polymerase chain reaction confirmed the TB meningitis. During hospitalization, a temporary EVD (external ventricular drain) was initially inserted. Eventually, defervescence was denoted 5-6 days after initiation of anti-TB medications, and a permanent ventriculoperitoneal shunt was inserted due to hydrocephalus. Gradually his truncal and limb tone and motor function improved, as did his emotional responses to his parents and ability to eat. The patient can walk without help in the 15th month following the operation and resolved hydrocephalus demonstrated on follow-up imaging.
CONCLUSION: Over half of treated TB meningitis patients die or suffer severe neurological sequelae, mainly due to late diagnosis. Hence, early diagnosis and prompt initiation of TB treatment offer the best chance of a good neurological outcome.
The extensive use of opioids for chronic pain management has contributed significantly to the current opioid epidemic. While many alternative nonopioid analgesics are available, opioids remain the most potent analgesics for moderate to severe pain management. In addition to the implementation of multimodal analgesia, there is a pressing need for the development of more effective and safer opioids. In this study, we developed a thermoresponsive N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-based hydromorphone (HMP) prodrug (ProGel-HMP, HMP content = 16.2 wt %, in base form). The aqueous solution of ProGel-HMP was free-flowing at 4 °C but became a hydrogel when the temperature was raised to ≥37 °C, allowing sustained local retention when administered in vivo. When tested in the destabilization of the medial meniscus (DMM) mouse model of osteoarthritis (OA), ProGel-HMP was retained after intra-articular injection in the OA knee joint for at least 2 weeks postinjection, with low extra-articular distribution. ProGel-HMP was not detected in the central nervous system (CNS). A single dose of ProGel-HMP produced rapid and sustained joint pain resolution for greater than 14 days when compared to saline and dose-equivalent HMP controls, likely mediated through peripheral μ-opioid receptors in the knee joint. Systemic analgesia effect was absent in the DMM mice treated with ProGel-HMP, as evident in the lack of difference in tail flick response between the ProGel-HMP-treated mice and the controls (i.e., Healthy, Saline, and Sham). Repeated dosing of ProGel-HMP did not induce tolerance. Collectively, these data support the further development of ProGel-HMP as a potent, safe, long-acting and nonaddictive analgesic for better clinical pain management.
Mast cells (MC) are ubiquitous in the body, and they are critical for not only in allergic diseases but also in immunity and inflammation, including having potential involvement in the pathophysiology of dysautonomias and neuroinflammatory disorders. MC are located perivascularly close to nerve endings and sites such as the carotid bodies, heart, hypothalamus, the pineal gland, and the adrenal gland that would allow them not only to regulate but also to be affected by the autonomic nervous system (ANS). MC are stimulated not only by allergens but also many other triggers including some from the ANS that can affect MC release of neurosensitizing, proinflammatory, and vasoactive mediators. Hence, MC may be able to regulate homeostatic functions that seem to be dysfunctional in many conditions, such as postural orthostatic tachycardia syndrome, autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, and Long-COVID syndrome. The evidence indicates that there is a possible association between these conditions and diseases associated with MC activation. There is no effective treatment for any form of these conditions other than minimizing symptoms. Given the many ways MC could be activated and the numerous mediators released, it would be important to develop ways to inhibit stimulation of MC and the release of ANS-relevant mediators.
FIELD: medicine.SUBSTANCE: method involves a pneumoroentgenography by placing a patient on a trochoscope of an X-ray diagnostic apparatus in a dorsosacral position with a pelvis elevated. A manipulation area is limited with sterile drapes, and the skin is treated with an antiseptic solution. A protruding part of the recurrent tumour is palpated to localise and smeared with a water-soluble contrast agent of diatriazole group. The same contrast agent is administered sub- and paratumorally from 4 points around the periphery of the new growth: 2 ml in one point. Thereafter, gas is injected at a depth of 5-6 cm around the periphery of the new growth into 6-10 points at 1.0-1.5 cm in an amount of 1.5-2.0 cmof gas into each point. That is followed by forming an X-ray image in a frontal projection and two semi-lateral projections; if observing a highlighted shadow with sharp bossed contours and more compact structure against the background of gas insufflated tissues of postoperative scar, recurrent carcinoma of vulva is diagnosed, a degree of expansion and an invasion depth of the tumour are determined.EFFECT: technique provides the accurate differentiation of the tumour and surrounding tissues and the accurate diagnosis of the degree of expansion and the invasion depth of recurrent carcinoma of vulva within the postoperative scar for the purpose of choosing the following adequate treatment.2 ex
According to an embodiment of the present invention, a heterogeneous hydrogel patch manufacturing device comprises: a first rotating body and a second rotating body; a first solution supplying and a second solution supplying unit; and guides. The first rotating body and a second rotating body are spaced a predetermined distance from each other to be disposed in parallel to each other, and rotate in different directions from each other. The first solution supplying unit and the second solution supplying unit input different solutions from each other between the first rotating body and the second rotating body. In guides, a first film is supplied to an outer circumference of the first rotating body, the second film is supplied to an outer circumference of the second rotating body, and when the solutions are inputted to an upper part of the gap, a lower surface is faced to outer circumferences of the rotating bodies to form a hydrogel patch to make a boundary of the solutions by compressing the solutions with the films in a lower part of the gap. When the solutions are inputted to the upper part, the guides are formed in a flat shape in lower parts of the solution supplying units to block mixing. In addition, the guides are detached from a fixing body for fixing the rotating bodies, and at least one of the rotating bodies is formed to allow a rotating shaft to be movable. The present invention can provide a 3D effect to the hydrogel patch.